Early outcomes of partial gland (focal) salvage brachytherapy for radiorecurrent prostate cancer
Brachytherapy · 2026-07 · 25 (4) · 648-657
DOI: 10.1016/j.brachy.2026.03.012 ↗Kurz gefasst
Fachartikel in der Zeitschrift Brachytherapy, 2026-07. Verfasst von Aneesh Dhar und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Brachytherapy, Salvage Therapy, Neoplasm Recurrence, Local. Die Arbeit nennt 23 Literaturangaben. Gefördert von: AlphaTau Medical, Memorial Sloan Kettering Cancer Center, American Austrian Foundation.
Abstract (Originalsprache)
PURPOSE Whole gland brachytherapy is an effective treatment for radiorecurrent prostate cancer. Partial gland (focal) treatment may provide equal efficacy with an improved toxicity profile for appropriate patients. METHODS AND MATERIALS We conducted a retrospective review of 100 patients who underwent focal HDR (19 Gy/1, HDR1; 22 Gy/2, HDR2) or LDR (Pd-103) brachytherapy between January 2017 and December 2024. All patients had prostate biopsies and the majority had MRI and/or PET imaging. ADT was used in 57 patients. Patients were followed with PSA, toxicity, and quality of life assessments. Nadir + 2 definition was used for biochemical failure (BF). Biochemical progression-free survival (bPFS), local failure-free survival (LFFS), toxicities, and quality of life were compared using Kaplan-Meier, Cox regression, and Chi-squared analyses. The median follow-up for the entire cohort was 26.5 months. RESULTS The 3-year bPFS (95% CI) for the HDR1, HDR2, and LDR cohorts were 72.3% (60.0-87.1), 84.0% (64.9-100), and 50% (12.5-100), respectively. On multivariate analyses, the only significant predictor for bPFS was presalvage PSA (p = 0.03). Local failure was only seen in the HDR1 cohort during the follow-up period. Grade 3+ GU and GI toxicities at 2-years for the entire cohort were 4.0% (0.0-8.5) and 2.8% (0.0-6.6), respectively. CONCLUSIONS Focal brachytherapy provides excellent early outcomes for patients with radiorecurrent prostate cancer. There was no difference in bPFS by brachytherapy type. There were no local failures in the HDR2 and LDR cohorts; however, follow up was short.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY.
- Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NY.
- Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY. Electronic address: kollmeim@mskcc.org.
Förderung
- AlphaTau Medical
- Memorial Sloan Kettering Cancer Center
- American Austrian Foundation
- National Institutes of Health
- MSD
- National Cancer Institute
Zitieren
APA
Dhar, A., Brennan, V., Pandya, S., Gorovets, D., Moore, A., Nagar, H., McBride, S., Damato, A. L., Beaudry, J., & Kollmeier, M. A. (2026). Early outcomes of partial gland (focal) salvage brachytherapy for radiorecurrent prostate cancer. Brachytherapy, 25(4), 648-657. https://doi.org/10.1016/j.brachy.2026.03.012
Vancouver
Dhar A, Brennan V, Pandya S, Gorovets D, Moore A, Nagar H, et al. Early outcomes of partial gland (focal) salvage brachytherapy for radiorecurrent prostate cancer. Brachytherapy. 2026;25(4):648-657. doi:10.1016/j.brachy.2026.03.012
BibTeX
@article{Dhar2026,
author = {Dhar, Aneesh and Brennan, Victoria and Pandya, Sankalp and Gorovets, Daniel and Moore, Assaf and Nagar, Himanshu and McBride, Sean and Damato, Antonio L and Beaudry, Joel and Kollmeier, Marisa A},
title = {Early outcomes of partial gland (focal) salvage brachytherapy for radiorecurrent prostate cancer},
journal = {Brachytherapy},
year = {2026},
volume = {25},
number = {4},
pages = {648--657},
doi = {10.1016/j.brachy.2026.03.012}
}
EUVIMED